Extraction outcomes of implantable cardioverter-defibrillator leads vary by manufacturer and model family
Open Access
- 24 November 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (12)
Abstract
Transvenous lead extraction (TLE) of implantable cardioverter-defibrillator (ICD) leads is considered challenging. The structure of each ICD leads is variable between manufacturer and model families. The net impact of lead family on the safety and effectiveness of TLE is poorly characterized. We assessed the safety and efficacy of ICD TLE and the impact of manufacturer ICD model family on the outcomes. The study cohort included all consecutive patients with ICD who underwent TLE between 2013 and 2022 and are enrolled in the Cleveland Clinic Prospective TLE Registry. A total of 885 ICD leads (median implant duration 8 years) in 810 patients were included. Complete ICD TLE success was achieved in 97.2% of the leads (n = 860) and in 98.0% of the patients (n = 794). Major complications occurred in 22 patients (2.7%). Complete procedural success rate varied by manufacturer and lead family; Medtronic 98.9%, Abbott 95.9%, Boston Scientific 95.0%, Biotronik 91.2%, P = 0.03, and Linox family leads had the lowest, 89.7% P = 0.02. Multivariable predictors of incomplete ICD lead removal included ICD lead age > 10 years and Linox family lead. Multivariable predictors of major complications included ICD lead age > 15 years and longer lead extraction time, and predictors of all-cause mortality within 30 days included lead extraction for infection, end-stage renal disease, and higher New York Heart Association functional class. Complete and safe ICD lead removal rate by TLE is extremely high but varied by manufacturer and lead family. Linox family lead and >10 years lead age were independent predictors of incomplete lead removal. ICD transvenous lead extraction outcomes by lead family. *Major complication is expressed by cases. Categorical data are presented as number (percentage). ICD, implantable cardioverter-defibrillator; HV, high voltage; LV, low voltage; PTFE, polytetrafluoroethylene insulation. Procedural success rate by transvenous lead extraction varied by lead family, P < 0.0001.Keywords
Funding Information
- Deb family endowed chair in Lead Management
This publication has 15 references indexed in Scilit:
- Long-term follow-up of abandoned transvenous defibrillator leads: a nationwide cohort studyEP Europace, 2020
- 2018 EHRA expert consensus statement on lead extraction: recommendations on definitions, endpoints, research trial design, and data collection requirements for clinical scientific studies and registries: endorsed by APHRS/HRS/LAHRSEP Europace, 2018
- Incidence and Predictors of Perioperative Complications With Transvenous Lead ExtractionsCirculation: Arrhythmia and Electrophysiology, 2018
- 2017 HRS expert consensus statement on cardiovascular implantable electronic device lead management and extractionHeart Rhythm, 2017
- The European Lead Extraction ConTRolled (ELECTRa) study: a European Heart Rhythm Association (EHRA) Registry of Transvenous Lead Extraction OutcomesEuropean Heart Journal, 2017
- Major predictors of fibrous adherences in transvenous implantable cardioverter-defibrillator lead extractionHeart Rhythm, 2014
- Clinical predictors of adverse patient outcomes in an experience of more than 5000 chronic endovascular pacemaker and defibrillator lead extractionsHeart Rhythm, 2014
- Superior Vena Cava Defibrillator Coils Make Transvenous Lead Extraction More Challenging and RiskierJACC, 2013
- Lead Extraction in the Contemporary Setting: The LExICon StudyJACC, 2010
- Insulation Lead Failure: Is it a Matter of Insulation Coating, Venous Approach, or Both?Pacing and Clinical Electrophysiology, 1998